April 12, 2018 / 12:28 PM / 5 months ago

BRIEF-Invokana Demonstrates Renal Protective Benefits In Patients With Type 2 Diabetes Mellitus And Chronic Kidney Disease

April 12 (Reuters) - Johnson & Johnson:

* INVOKANA® (CANAGLIFLOZIN) DEMONSTRATED SIGNIFICANT RENAL PROTECTIVE BENEFITS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE

* ANALYSIS SHOWING INVOKANA IMPROVED RENAL OUTCOMES IN PEOPLE WITH TYPE 2 DIABETES MELLITUS WITH/AT HIGH RISK FOR CV DISEASE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below